{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:08:09Z","timestamp":1783940889460,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"DOI":"10.1007\/s00702-026-03213-0","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:54:18Z","timestamp":1783940058000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of amantadine in the treatment of fatigue in multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7065-381X","authenticated-orcid":false,"given":"Ahmed Mostafa","family":"Amin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5624-0017","authenticated-orcid":false,"given":"Muataz","family":"Kashbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6104-7798","authenticated-orcid":false,"given":"Ahmed Fawzy","family":"Alsokery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4080-4154","authenticated-orcid":false,"given":"Ahmed","family":"Nady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0891-3561","authenticated-orcid":false,"given":"Mohamed","family":"Wagdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1268-3649","authenticated-orcid":false,"given":"Ahmed ElSayed","family":"Awadallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Reda","family":"Aboyadak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0692-6309","authenticated-orcid":false,"given":"Mostafa","family":"Meshref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"5","key":"3213_CR2","first-page":"428","volume":"43","author":"F Ashtari","year":"2009","unstructured":"Ashtari F, Fatehi F, Shaygannejad V, Chitsaz A (2009) Does amantadine have favourable effects on fatigue in persian patients suffering from multiple sclerosis? Neurol Neurochir Pol 43(5):428\u2013432","journal-title":"Neurol Neurochir Pol"},{"issue":"2","key":"3213_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.neucli.2017.02.004","volume":"47","author":"SS Ayache","year":"2017","unstructured":"Ayache SS, Chalah MA (2017) Fatigue in multiple sclerosis\u2014insights into evaluation and management. Neurophysiol Clin Clin Neurophysiol 47(2):139\u2013171. https:\/\/doi.org\/10.1016\/j.neucli.2017.02.004","journal-title":"Neurophysiologie Clinique = Clin Neurophysiol"},{"issue":"1","key":"3213_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/1352458519851247","volume":"26","author":"F Capone","year":"2020","unstructured":"Capone F, Collorone S, Cortese R, Lazzaro VD, Moccia M (2020) Fatigue in multiple sclerosis: the role of thalamus. Mult Scler 26(1):6\u201316. https:\/\/doi.org\/10.1177\/1352458519851247","journal-title":"Mult Scler"},{"issue":"9413","key":"3213_CR5","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S0140-6736(04)15794-2","volume":"363","author":"A Chaudhuri","year":"2004","unstructured":"Chaudhuri A, Behan PO (2004) Fatigue in neurological disorders. Lancet (London England) 363(9413):978\u2013988. https:\/\/doi.org\/10.1016\/S0140-6736(04)15794-2","journal-title":"Lancet (London England)"},{"issue":"6","key":"3213_CR8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/archneur.1989.00520420096030","volume":"46","author":"RA Cohen","year":"1989","unstructured":"Cohen RA, Fisher M (1989) Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 46(6):676\u2013680. https:\/\/doi.org\/10.1001\/archneur.1989.00520420096030","journal-title":"Arch Neurol"},{"issue":"4","key":"3213_CR7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1177\/1352458518754716","volume":"25","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Samuel F, Hunter, Theodore R, Brown et al (2019) Safety and efficacy of ADS-5102 (Amantadine) extended release capsules to improve walking in multiple sclerosis: a randomized, placebo-controlled, phase 2 trial. Mult Scler 25(4):601\u2013609. https:\/\/doi.org\/10.1177\/1352458518754716","journal-title":"Mult Scler"},{"issue":"5","key":"3213_CR6","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/13524585211035333","volume":"28","author":"JA Cohen","year":"2022","unstructured":"Cohen JA, Cameron MH, Goldman MD et al (2022) A phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. Mult Scler 28(5):817\u2013830. https:\/\/doi.org\/10.1177\/13524585211035333","journal-title":"Mult Scler"},{"issue":"1","key":"3213_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1185\/03007995.2011.639752","volume":"28","author":"CI Coleman","year":"2012","unstructured":"Coleman CI, Sobieraj DM, Marinucci LN (2012) Minimally important clinical difference of the timed 25-foot walk test: results from a randomized controlled trial in patients with multiple sclerosis. Curr Med Res Opin 28(1):49\u201356. https:\/\/doi.org\/10.1185\/03007995.2011.639752","journal-title":"Curr Med Res Opin"},{"key":"3213_CR10","doi-asserted-by":"publisher","unstructured":"Danysz W, Dekundy A, Scheschonka A, Riederer P (2021) Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials. J Neural Transm (Vienna, Austria: 1996) 128 (2):127\u201369. https:\/\/doi.org\/10.1007\/s00702-021-02306-2","DOI":"10.1007\/s00702-021-02306-2"},{"issue":"Pt 3","key":"3213_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1348\/1359107041557048","volume":"9","author":"J De Vries","year":"2004","unstructured":"De Vries J, Michielsen H, Van Heck GL, and Marjolein Drent (2004) Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 9(Pt 3):279\u2013291. https:\/\/doi.org\/10.1348\/1359107041557048","journal-title":"Br J Health Psychol"},{"issue":"7109","key":"3213_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res Ed) 315(7109):629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ (Clinical Res Ed)"},{"key":"3213_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"J Higgins","year":"2019","unstructured":"Higgins J, Thomas J, Chandler J et al (2019) Cochrane handbook for systematic reviews of interventions. Wiley Cochrane, 2nd edn. John Wiley & Sons, Incorporated","edition":"2"},{"issue":"16","key":"3213_CR14","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1212\/WNL.0b013e31828cf7f3","volume":"80","author":"J Hobart","year":"2013","unstructured":"Hobart J, Blight AR, Goodman A, Lynn F, Putzki N (2013) Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology 80(16):1509\u20131517. https:\/\/doi.org\/10.1212\/WNL.0b013e31828cf7f3","journal-title":"Neurology"},{"issue":"11","key":"3213_CR15","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1212\/wnl.45.11.1956","volume":"45","author":"LB Krupp","year":"1995","unstructured":"Krupp LB, Coyle PK, Doscher C et al (1995) Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 45(11):1956\u20131961. https:\/\/doi.org\/10.1212\/wnl.45.11.1956","journal-title":"Neurology"},{"issue":"8","key":"3213_CR16","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1093\/brain\/awx153","volume":"140","author":"A Kuppuswamy","year":"2017","unstructured":"Kuppuswamy A (2017) The fatigue conundrum. Brain 140(8):2240\u20132245. https:\/\/doi.org\/10.1093\/brain\/awx153","journal-title":"Brain"},{"issue":"December","key":"3213_CR17","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/j.clineuro.2013.09.029","volume":"115","author":"A Ledinek","year":"2013","unstructured":"Ledinek AH, Sajko MC, Rot U (2013) Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis\u2013result of a pilot randomized, blind study. Clin Neurol Neurosurg 115:S86\u201389. https:\/\/doi.org\/10.1016\/j.clineuro.2013.09.029","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"3213_CR18","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1136\/jnnp-2018-320050","volume":"90","author":"Z-M Manjaly","year":"2019","unstructured":"Manjaly Z-M, Harrison NA, Critchley HD et al (2019) Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry 90(6):642\u2013651. https:\/\/doi.org\/10.1136\/jnnp-2018-320050","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"March","key":"3213_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jneuroim.2015.01.011","volume":"280","author":"P Mulero","year":"2015","unstructured":"Mulero P, Almansa R, Neri MJ et al (2015) Improvement of fatigue in multiple sclerosis by physical exercise is associated to modulation of systemic interferon response. J Neuroimmunol 280:8\u201311. https:\/\/doi.org\/10.1016\/j.jneuroim.2015.01.011","journal-title":"J Neuroimmunol"},{"issue":"3","key":"3213_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1017\/s0317167100047107","volume":"12","author":"TJ Murray","year":"1985","unstructured":"Murray TJ (1985) Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 12(3):251\u2013254. https:\/\/doi.org\/10.1017\/s0317167100047107","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"3213_CR21","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/10790268.2016.1168587","volume":"39","author":"P Newland","year":"2016","unstructured":"Newland P, Starkweather A, Sorenson M (2016) Central fatigue in multiple sclerosis: a review of the literature. J Spinal Cord Med 39(4):386\u2013399. https:\/\/doi.org\/10.1080\/10790268.2016.1168587","journal-title":"J Spinal Cord Med"},{"issue":"1","key":"3213_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(20)30354-9","volume":"20","author":"B Nourbakhsh","year":"2021","unstructured":"Nourbakhsh B, Revirajan N, Morris B et al (2021) Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol 20(1):38\u201348. https:\/\/doi.org\/10.1016\/S1474-4422(20)30354-9","journal-title":"Lancet Neurol"},{"issue":"1","key":"3213_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Reviews 5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Reviews"},{"issue":"April","key":"3213_CR24","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg (London England) 88(April):105906. https:\/\/doi.org\/10.1016\/j.ijsu.2021.105906","journal-title":"Int J Surg (London England)"},{"issue":"6","key":"3213_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2217\/nmt-2020-0030","volume":"10","author":"DQ Perez","year":"2020","unstructured":"Perez DQ, Espiritu AI, Jamora RD (2020) Efficacy and safety of amantadine for the treatment of fatigue in multiple sclerosis: a systematic review and meta-analysis. Neurodegener Dis Manag 10(6):383\u2013395. https:\/\/doi.org\/10.2217\/nmt-2020-0030","journal-title":"Neurodegenerative Disease Manage"},{"issue":"1","key":"3213_CR26","doi-asserted-by":"publisher","first-page":"CD002818","DOI":"10.1002\/14651858.CD002818.pub2","volume":"2007","author":"E Pucci","year":"2007","unstructured":"Pucci E, Bra\u00f1as P, D'Amico R, Giuliani G, Solari A, Taus C (2007) Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2007(1):CD002818. https:\/\/doi.org\/10.1002\/14651858.CD002818.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"3213_CR27","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1111\/ene.14867","volume":"28","author":"MA Rocca","year":"2021","unstructured":"Rocca MA, Valsasina P, Colombo B, Martinelli V, Filippi M (2021) Cortico\u2010subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. Eur J Neurol 28(7):2249\u20132258. https:\/\/doi.org\/10.1111\/ene.14867","journal-title":"Eur J Neurol"},{"issue":"October","key":"3213_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.msard.2019.07.028","volume":"35","author":"S Rooney","year":"2019","unstructured":"Rooney S, McFadyen A, Wood L, Moffat F, Paul L (2019) Minimally important difference of the fatigue severity scale and modified fatigue impact scale in people with multiple sclerosis. Mult Scler Relat Disord 35:158\u2013163. https:\/\/doi.org\/10.1016\/j.msard.2019.07.028","journal-title":"Multiple Scler Relat Disorders"},{"issue":"August","key":"3213_CR29","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"3213_CR1","doi-asserted-by":"publisher","unstructured":"The Canadian MS Research Group (1987) A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 14(3):273\u2013278. https:\/\/doi.org\/10.1017\/s0317167100026603","DOI":"10.1017\/s0317167100026603"},{"issue":"2","key":"3213_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"issue":"April","key":"3213_CR31","doi-asserted-by":"publisher","first-page":"106352","DOI":"10.1016\/j.msard.2025.106352","volume":"96","author":"K Toljan","year":"2025","unstructured":"Toljan K, Aboseif A, Amin M (2025) Efficacy of pharmacologic treatments for fatigue in multiple sclerosis: a systematic review and meta-analysis. Multiple Scler Relat Disord 96:106352. https:\/\/doi.org\/10.1016\/j.msard.2025.106352","journal-title":"Multiple Scler Relat Disorders"},{"issue":"6","key":"3213_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11940-016-0411-8","volume":"18","author":"C Tur","year":"2016","unstructured":"Tur C (2016) Fatigue management in multiple sclerosis. Curr Treat Options Neurol 18(6):26. https:\/\/doi.org\/10.1007\/s11940-016-0411-8","journal-title":"Curr Treat Options Neurol"},{"issue":"December","key":"3213_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135","journal-title":"BMC Med Res Methodol"},{"issue":"September","key":"3213_CR34","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jns.2017.07.042","volume":"380","author":"T-T Yang","year":"2017","unstructured":"Yang T-T, Wang L, Deng X-Y, Yu G (2017) Pharmacological treatments for fatigue in patients with multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci 380:256\u2013261. https:\/\/doi.org\/10.1016\/j.jns.2017.07.042","journal-title":"J Neurol Sci"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03213-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03213-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03213-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:54:19Z","timestamp":1783940059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-026-03213-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":34,"alternative-id":["3213"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03213-0","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This systematic review and meta-analysis did not involve direct participation of individuals, so ethical approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"We declare that this research paper has not been published elsewhere in any other academic journal or platform.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous publication"}},{"value":"We declare that we have not used AI in writing any part of this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI in scientific writing"}}]}}